Get started
Work

Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

Year: 2022
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs21-ot2-11-04
Authors: Mario Campone, Sarat Chandarlapaty, Aditya Bardia, Patrick Neven, Katarina Petrakova, Peter Kabos, Valentina Boni, Sofia Braga, Marina Celanovic, Patrick Cohen, Alice Gosselin, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Hannah Linden
Institutions: Institut de Cancérologie de l'Ouest, Memorial Sloan Kettering Cancer Center, Harvard University, Massachusetts General Hospital, Universitair Ziekenhuis Leuven, HM Hospitales, Hospital Universitario HM Sanchinarro, Sanofi (France), Seattle Cancer Care Alliance, University of Washington Medical Center
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4221124594
Cites:
Cited by: 1
Related to: 10